A Study of Mirikizumab in Participants With Plaque Psoriasis

I6T-MC-AMBP -

This study is known as a "drug interaction study". The purpose is to learn how commonly used drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and their breakdown products get into the bloodstream after taking a "cocktail" (combination) of them before and after multiple doses of mirikizumab. The study will last about 23 weeks for each participant. Screening must be completed within 4 weeks prior to study start.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Plaque Psoriasis
What the trial is testing?
Mirikizumab (LY3074828)
Could I receive a Placebo?
No
Enrollment Goal
29
Trial Dates
Oct 23, 2018 - Oct 28, 2019
How long will I be in the trial?
The study will last about 23 weeks for each participant, which includes 10 outpatient visits and 2 inpatient visits (with 3 overnights per visit).
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.